Mitchell P - Search Results

1

Loss of STING expression is prognostic in non-small cell lung cancer.

Lohinai Z, Dora D, Caldwell C, Rivard CJ, Suda K, Yu H, Rivalland G, Ellison K, Rozeboom L, Dziadziuszko R, Mitchell P, John T, Millan IS, Ren S, Hirsch FR. Lohinai Z, et al. Among authors: mitchell p. J Surg Oncol. 2022 May;125(6):1042-1052. doi: 10.1002/jso.26804. Epub 2022 Jan 31. J Surg Oncol. 2022. PMID: 35099823 Free PMC article.

2

The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.

Ren S, Tian Q, Amar N, Yu H, Rivard CJ, Caldwell C, Ng TL, Tu M, Liu Y, Gao D, Ellison K, Suda K, Rozeboom L, Rivalland G, Mitchell P, Zhou C, Hirsch FR. Ren S, et al. Among authors: mitchell p. Lung Cancer. 2018 Nov;125:115-120. doi: 10.1016/j.lungcan.2018.09.004. Epub 2018 Sep 12. Lung Cancer. 2018. PMID: 30429008

3

Lung cancer in 2016: immunotherapy comes of age.

Mitchell PL, John T. Mitchell PL, et al. Lancet Respir Med. 2016 Dec;4(12):947-949. doi: 10.1016/S2213-2600(16)30379-4. Epub 2016 Nov 22. Lancet Respir Med. 2016. PMID: 27890503 No abstract available.

4

A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma.

Do H, Wong NC, Murone C, John T, Solomon B, Mitchell PL, Dobrovic A. Do H, et al. Sci Rep. 2014 Feb 26;4:4186. doi: 10.1038/srep04186. Sci Rep. 2014. PMID: 24569633 Free PMC article.

5

NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.

Leal JL, Peters G, Szaumkessel M, Leong T, Asadi K, Rivalland G, Do H, Senko C, Mitchell PL, Quing CZ, Dobrovic A, Thapa B, John T. Leal JL, et al. Lung Cancer. 2020 Aug;146:154-159. doi: 10.1016/j.lungcan.2020.05.019. Epub 2020 May 24. Lung Cancer. 2020. PMID: 32540558

6

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors.

Chia PL, Mitchell P, Dobrovic A, John T. Chia PL, et al. Among authors: mitchell p. Clin Epidemiol. 2014 Nov 20;6:423-32. doi: 10.2147/CLEP.S69718. eCollection 2014. Clin Epidemiol. 2014. PMID: 25429239 Free PMC article. Review.

7

Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.

Arulananda S, Do H, Musafer A, Mitchell P, Dobrovic A, John T. Arulananda S, et al. Among authors: mitchell p. J Thorac Oncol. 2017 Nov;12(11):1728-1732. doi: 10.1016/j.jtho.2017.08.006. Epub 2017 Aug 24. J Thorac Oncol. 2017. PMID: 28843359 Free article.

8

De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer.

Thai A, Chia PL, Russell PA, Do H, Dobrovic A, Mitchell P, John T. Thai A, et al. Among authors: mitchell p. Intern Med J. 2017 Sep;47(9):1071-1074. doi: 10.1111/imj.13531. Intern Med J. 2017. PMID: 28891180

9

Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort.

Rivalland G, Mitchell P, Murone C, Asadi K, Morey AL, Starmans M, Boutros PC, Walkiewicz M, Solomon B, Wright G, Knight S, John T. Rivalland G, et al. Among authors: mitchell p. Transl Lung Cancer Res. 2019 Apr;8(2):167-175. doi: 10.21037/tlcr.2019.03.11. Transl Lung Cancer Res. 2019. PMID: 31106127 Free PMC article.

10

Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease.

Arulananda S, Do H, Rivalland G, Loh Z, Musafer A, Lau E, Mitchell P, Dobrovic A, John T. Arulananda S, et al. Among authors: mitchell p. J Thorac Dis. 2019 May;11(5):1756-1764. doi: 10.21037/jtd.2019.05.41. J Thorac Dis. 2019. PMID: 31285867 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,340 results

Search Page